Sign in

KAPA on NYSE

Kairos Pharma, LTD.

Kairos Pharma, LTD. is an American pharmaceutical preparations company based in Los Angeles.1 Its shares trade on NYSE under the symbol KAPA.1

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with another stock.

  • TickerKAPA on NYSE1
  • IndustryPharmaceutical Preparations1
  • HeadquartersLos Angeles, California1
  • Incorporated inDE2
  • Business address2355 Westwood Blvd. #139, Los Angeles, Ca 900642
  • Filer category, Emerging growth company2
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

101 is a small molecule that targets the GITR ligand, a signal for T cell growth to remove a checkpoint barrier to fight a host of cancers.3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Products and services

Item 4 brought in 91% of the revenue Kairos Pharma, LTD. broke down this way in fiscal 2025.

  1. Item 4$50.0M491%
  2. Item 1, 2 and 3$5.0M59%
Products and services by year
Products and services2025
Item 4$50.0M
Item 1, 2 and 3$5.0M

Financial statements

Operating income64-$5.6M in 2025+225% since 2023
-$6.0M-$4.0M-$2.0M02023: -$1.7M-$1.7M20232024: -$2.3M-$2.3M2024+37%2025: -$5.6M-$5.6M2025+138%
Net income64-$5.4M in 2025+201% since 2023
-$6.0M-$4.0M-$2.0M02023: -$1.8M-$1.8M20232024: -$2.6M-$2.6M2024+44%2025: -$5.4M-$5.4M2025+109%

Every line of the income statement as filed: the last 2 fiscal years, latest first.4

Period ending2025-12-312024-12-31
Research and development$2.1M$414.0K
General and administrative$3.4M$1.9M
Total operating expenses$5.6M$2.3M
Loss from operations-$5.6M-$2.3M
Interest expense-$35.0K
Debt discount amortization-$154.0K
Financing costs-$670.0K
Gain on settlement of accounts payable$599.0K
Interest income$125.0K
Total other income (expenses)$125.0K-$260.0K
NET LOSS-$5.4M-$2.6M
BASIC LOSS PER COMMON SHARE-$0.30-$0.23
DILUTED LOSS PER COMMON SHARE-$0.30-$0.23
WEIGHTED-AVERAGE COMMON SHARES OUTSTANDING BASIC18.4M shares11.4M shares
WEIGHTED-AVERAGE COMMON SHARES OUTSTANDING DILUTED18.4M shares11.4M shares

Compare Kairos Pharma, LTD. with another company

Corporate structure

Kairos Pharma, LTD. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Kairos Pharma, LTD.

  • ARMISTICE CAPITAL, LLC Filed SCHEDULE 13G/A on Kairos Pharma, LTD., latest Aug 14, 2025 (2 filings since May 15, 2025)
  • Kairos Pharma, LTD. Los Angeles, California

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Kairos Pharma, LTD. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$4.5M4 Dec 31, 2025$1.3M4 Dec 31, 2024+253.1%

Intangibles and goodwill

ItemLatestA year beforeChange
Intangible assets, net (excluding goodwill)$62.0K4 Dec 31, 2025$222.0K4 Dec 31, 2024−72.1%

Properties, in its own words

Our corporate address is 2355 Westwood Blvd. #139, Los Angeles, CA, 90064. This is the address of our registered agent. We currently do not lease any properties, but if required, we believe that suitable additional or alternative space would be available in the future on commercially reasonable terms. As of the date of this Annual Report, all of our operations are conducted virtually.

Item 2 of the 10-K filed Mar 31, 2026.3

Leadership

Who has led Kairos Pharma, LTD., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. John S. Yu2024–now

Chair

  1. John S. Yu2024–now
2025
Board members and other officers (6)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • Chief Financial OfficerDoug S. Samuelson named Apr 27, 2023 to Jan 28, 202515

Timeline

  1. Oct 6, 20268-K Other events16
  2. Sep 14, 20268-K Regulation FD disclosure17
  3. Aug 21, 20268-K Change to shareholders' rights; Bylaws or fiscal year changed; Regulation FD disclosure18
  4. Jul 22, 20268-K Entered a material agreement; Other events19
  5. Jul 15, 20268-K Other events20
  6. Jun 30, 20268-K Shareholder vote21
  7. Jun 4, 20268-K Other events22
  8. May 18, 20268-K Other events23
  9. Mar 2, 20268-K Entered a material agreement; Other events24
  10. Feb 26, 20268-K Other events25
  11. Oct 15, 20258-K Executive or director change26
  12. Oct 7, 20258-K Entered a material agreement; Other events27
  13. Sep 24, 2024New chief executive John S. Yu becomes CEO8

Calendar

Coming up

  1. Nov 13, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($0.49) a share, on Nov 14, 2025.28

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

123 filings to the SEC since October 2021: 4 annual reports, 6 quarterly reports, 32 major events, 21 insider forms, 2 large holders, 2 private raises, 56 other. The latest 20:

  1. Oct 6, 20268-K EDGAR
  2. Sep 14, 20268-K EDGAR
  3. Aug 21, 20268-K EDGAR
  4. Aug 12, 202610-Q EDGAR
  5. Jul 22, 20268-K EDGAR
  6. Jul 15, 20268-K EDGAR
  7. Jun 30, 20268-K EDGAR
  8. Jun 4, 20268-K EDGAR
  9. May 26, 2026DEFA14A EDGAR
  10. May 22, 2026ARS EDGAR
  11. May 22, 2026DEF 14A EDGAR
  12. May 18, 20268-K EDGAR
  13. May 13, 202610-Q EDGAR
  14. May 11, 2026PRE 14A EDGAR
  15. Apr 1, 2026424B3 EDGAR
  16. Apr 1, 2026424B3 EDGAR
  17. Mar 31, 202610-K EDGAR
  18. Mar 2, 20268-K EDGAR
  19. Feb 26, 20268-K EDGAR
  20. Jan 23, 2026EFFECT EDGAR

The 123 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

3 open-market trades by officers, directors and large owners since October 2021: 3 buys and 0 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Nov 25, 2024Murali RamachandranVP of Research and DevelopmentBuy200$1.59$318Form 4
Nov 22, 2024Samuelson DougChief Financial OfficerBuy2,500$1.50$3.8KForm 4
Nov 20, 2024Yu John SCEO and ChairmanBuy4,000$1.44$5.8KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2025John S. Yu61$200.0K$362.9K30
2025Doug Samuelson66$62.5K$254.8K30
2025Neil Bhowmick$106.2K$225.4K30
2025Ramachandran Murali$87.5K$190.4K30
2024Doug Samuelson66$14.7K$137.7K30
2024John S. Yu61$51.3K$85.7K30
2024Neil Bhowmick$29.3K$72.8K30
2024Ramachandran Murali$23.5K$63.9K30

Funding

Where the company's money came from, by calendar year: private offerings filed with the SEC, federal grants, loans, contracts and other assistance from USAspending.gov, and PPP loans from the SBA. Each bar links to the records below.

Money received by year$4.2M 2022–2025
Money received by yearMoney received by year, 2022–2025: $4.2M in all. Private raises (Form D) $4.2M.$0$1M$2M$3M$4M2022 · Private raises (Form D): $675.0K2022202320242025 · Private raises (Form D): $3.5M2025
Figures by year
YearPrivate raises (Form D)Total
2025$3.5M$3.5M
2022$675.0K$675.0K

Private raises

Private offerings the company reported to the SEC on Form D. The amount is what the latest filing says was sold so far, charted in the year of the first sale. Covers filings since Oct 1, 2021.

  1. Jan 16, 2025Raised $3.5 million in a private offering of securities15 Form D: $8.8 million offered in all Form D
  2. Jun 30, 2022Raised $675,000 in a private offering of debt31 Form D: $3 million offered in all Form D

SEC filer profile

How Kairos Pharma, LTD. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARKairos Pharma, LTD.1
  • CIK0001962011
  • Employer ID (EIN)46-29933143
  • Filer statusNon-accelerated filer an emerging growth company; a smaller reporting company; a shell company3
  • Incorporated inDelaware3
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address2355 Westwood Blvd. #139, Los Angeles, CA 900641
  • Phone818-404-55411
  • Shares outstanding23,697,683 as of Aug 12, 20267
  • Public float$6.9M as of Jun 30, 20253
  • AuditorWeinberg & Company P.A., Los Angeles, CA PCAOB ID 572; no auditor attestation of internal control over financial reporting3
  • On EDGAR sinceMar 29, 20231
  • Filings123 in all: 8-K (32), 4 (13), CORRESP (9), 3 (8), S-1/A (8), 10-Q (6), 424B3 (5), UPLOAD (5)1
    All 32 form types

    EFFECT (4), DRS/A (3), S-1 (3), 10-K (2), 10-K/A (2), D (2), DEF 14A (2), DRS (2), DRSLTR (2), 424B4 (1), 8-A12B (1), ARS (1), CERT (1), DEF 14C (1), DEFA14A (1), DEFR14A (1), NT 10-K (1), PRE 14A (1), PRE 14C (1), PRER14A (1), S-3 (1), S-8 (1), SCHEDULE 13G (1), SCHEDULE 13G/A (1)

  • Latest filingsAnnual report (10-K) Mar 31, 2026
    Quarterly report (10-Q) Aug 12, 2026
    Proxy statement (DEF 14A) May 22, 2026
    Latest 8-K (8-K) Oct 6, 2026

Securities registered for trading

ClassSymbolExchange
Common Stock, par value $0.001 per shareKAPANYSE American

From the cover page of the 10-K filed Mar 31, 2026 (Section 12(b) of the Exchange Act).3

Risk factors and legal proceedings

The risks Kairos Pharma, LTD. names in Item 1A of its 10-K filed Mar 31, 2026: 75 risks under these headings, as written.3

  • Risks Related to Our Financial Position and Capital Needs
  • We are a small development-stage biopharmaceutical company with a limited operating history and no products approved for commercial sale. We have incurred significant losses since our inception. We expect to incur losses over the next several years and may never achieve or maintain profitability.
  • We require substantial additional funding to meet our financial needs and to pursue our business objectives. If we are unable to raise capital when needed, we could be forced to delay, reduce, or altogether cease our current and future product development programs or future commercialization efforts.
  • Raising additional capital will likely cause dilution to our stockholders, restrict our operations, or require us to relinquish rights to our current in-development products or technologies or any of our future product candidates.
  • Our limited operating history may make it difficult for you to evaluate the success of our business to date and to assess our future viability.
  • We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or have a greater likelihood of success.
  • Risks Related to Development, Clinical Testing, Manufacturing and Regulatory Approval
  • We are heavily dependent on the success of our initial drug candidates, which are still under clinical development, and if any of these drugs does not receive regulatory approval or is not successfully commercialized, our business may be harmed.
  • If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals, we will not be able to commercialize our current in-development products or our future product candidates, and our ability to generate revenue will be materially impaired.
  • Preclinical development is uncertain. Our preclinical programs may experience delays or may never advance to clinical trials, which would adversely affect our ability to obtain regulatory approvals or commercialize these programs on a timely basis or at all.
  • Clinical trials are expensive, time-consuming and difficult to design and implement, and involve an uncertain outcome.
  • Future legislation, and/or regulations and policies adopted by the FDA, the EMA, or comparable regulatory authorities, may increase the time and cost required for us to conduct and complete clinical trials of our current in-development products or other future product candidates.
The other 65 risks
  • Our product candidates are based on novel technologies, which make it difficult to predict the timing, results and cost of product candidate development and likelihood of obtaining regulatory approval.
  • Serious adverse events, undesirable side effects or other unexpected properties of our product candidates may be identified during development or after approval, which could lead to the discontinuation of our clinical development programs, refusal by regulatory authorities to approve our product candidates or, if discovered following marketing approval, revocation of marketing authorizations or limitations on the use of our product candidates thereby limiting the commercial potential of such product candidate.
  • Positive results from preclinical studies and early-stage clinical trials may not be predictive of future results. Initial positive results in any of our clinical trials may not be indicative of results obtained when the trial is completed or in later stage trials.
  • As an organization, we have limited experience designing and implementing clinical trials and we have never conducted pivotal clinical trials. Failure to adequately design a trial, or incorrect assumptions about the design of the trial, could adversely affect the ability to initiate the trial, enroll patients, complete the trial, or obtain regulatory approval on the basis of the trial results, as well as lead to increased or unexpected costs and in delayed timelines.
  • Our business is dependent on our ability to advance our current and future product candidates through clinical trials, obtain marketing approval and ultimately commercialize them.
  • Interim, topline and preliminary data from our clinical trials may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.
  • We may face future business disruption and related risks resulting from pandemic, epidemic or outbreak of an infectious disease, any of which could have a material adverse effect on our business.
  • Disruptions at the FDA and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire, retain or deploy key leadership and other personnel, or otherwise prevent new or modified products from being developed, or approved or commercialized in a timely manner or at all, which could negatively impact our business.
  • We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.
  • We may not be successful in our efforts to identify or discover additional product candidates in the future.
  • The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time consuming, expensive, and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our drug therapy candidates, our business will be substantially harmed.
  • Enrollment and retention of patients in clinical trials is an expensive and time-consuming process and could be made more difficult or rendered impossible by multiple factors outside our control.
  • Results of preclinical studies, early clinical trials or analyses may not be indicative of results obtained in later trials.
  • The market opportunities for any current or future product candidate we develop, if approved, may be limited to those patients who are ineligible for established therapies or for whom prior therapies have failed, and may be small.
  • We have never obtained marketing approval for a drug therapy candidate and we may be unable to obtain, or may be delayed in obtaining, marketing approval for any of our development candidates.
  • Even if we obtain FDA approval for any of our drug therapy candidates in the United States, we may never obtain approval for or commercialize them in any other jurisdiction, which would limit our ability to realize their full global market potential.
  • Even if we obtain regulatory approval for any development candidate, we will still face extensive and ongoing regulatory requirements and obligations and any development candidates, if approved, may face future development and regulatory difficulties.
  • Even if we obtain marketing approvals for our current in-development products or any future product candidates, the terms of approvals and ongoing regulation of such product candidates may limit how we manufacture and market the product candidates and compliance with such requirements may involve substantial resources, which could materially impair our ability to generate revenue.
  • We may seek a Breakthrough Therapy designation for one of our drug therapy candidates from the FDA. However, we might not seek such designation or be granted the designation by the FDA if sought, and even if we are granted the designation, it may not lead to a faster development or regulatory review or approval process.
  • Risks Related to the Commercialization of Our Current In-Development Products and Our Future Product Candidates
  • Even if any of our current in-development products or any of our future product candidates receives marketing approval, it may fail to achieve the degree of market acceptance by physicians, patients, third-party payors, and others in the medical community necessary for commercial success.
  • If we are unable to establish sales, marketing, and distribution capabilities for our current in-development products or our future product candidates, or enter into sales, marketing, and distribution agreements with third parties, we may not be successful in commercializing our product candidates, if and when they are approved.
  • Coverage and adequate reimbursement may not be available for any of our in-development products or any future product candidates, which could make it difficult for us to sell profitably, if approved.
  • If we are unable to successfully develop any required companion diagnostic tests for our product candidates, experience significant delays in doing so, or rely on third parties in the development of such companion diagnostic tests, we may be unable to realize the full commercial potential of our product candidates.
  • Product liability lawsuits against us could cause us to incur substantial liabilities and to limit commercialization of any products that we may develop.
  • There are a variety of risks associated with marketing our current in-development products or any future product candidates internationally, which could affect our business.
  • Risks Related to Our Dependence on Third Parties
  • Our employees and independent contractors, including principal investigators, clinical trial sites, contract research organizations, or CROs, consultants, vendors, and any third parties we may engage in connection with development and commercialization, may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could have a material adverse effect on our business.
  • We rely on single-sourced third parties to conduct the preclinical and nonclinical studies, clinical trials, and manufacture of our clinical trial material for our current in-development products and our future product candidates, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such studies, trials, and manufacturing services or failing to comply with applicable regulatory requirements.
  • We will rely on third-party contract manufacturing organizations, or CMOs, for the production of clinical supply of our drug therapy candidates and intend to rely on CMOs for the production of commercial supply our drug therapies, if approved. Our dependence on CMOs may impair the development and commercialization of the drug, which would adversely impact our business and financial position.
  • Our reliance on single-sourced third parties to manufacture our product candidates increases the risk that we will not have sufficient quantities of our product candidates or products or such quantities at an acceptable cost, which could delay, prevent, or impair our development or commercialization efforts.
  • We intend to continue to rely on third parties to conduct, supervise and monitor our clinical trials. If those third parties do not successfully carry out their contractual duties, or if they perform in an unsatisfactory manner, it may harm our business.
  • The number and type of our collaborations could adversely affect our attractiveness to future collaborators or acquirers and the loss of, or a disruption in our relationship with, any one or more collaborators could harm our business.
  • We are relying exclusively on the skills and expertise of our management team in conducting our business, not all of whom will devote all of their time to managing the Company, and we currently only have one full-time employee, which may impede our ability to carry on our business.
  • We operate with a small team and our future success depends on our ability to retain key executives and to attract, retain, and motivate qualified personnel.
  • We face substantial competition from large, well-funded, and experienced competitors, which may result in others discovering, developing or commercializing products before or more successfully than we do.
  • We have identified material weaknesses in our internal control over financial reporting. If we are unable to remediate these material weaknesses, or if we identify additional material weaknesses in the future or otherwise fail to maintain effective internal control over financial reporting, we may not be able to accurately or timely report our financial condition or results of operations, which may adversely affect our business.
  • We expect to expand our research, development, and business capabilities and potentially implement sales, marketing, and distribution capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.
  • If we engage in future acquisitions or strategic collaborations, this may increase our capital requirements, dilute our stockholders, cause us to incur debt or assume contingent liabilities, and subject us to other risks.
  • Risks Related to Our Intellectual Property
  • Our exclusive licensing rights to our intellectual property are subject to agreements with third parties and we may not meet milestones set forth in those agreements; our exclusive licensing rights may be terminated.
  • If we are unable to obtain and maintain patent and other intellectual property protection for our technology, or for any our current in-development products or our future product candidates, or if the scope of the patent and other intellectual property protection obtained is not sufficiently broad, our competitors could develop and commercialize technology and drugs similar or identical to ours, and our ability to successfully commercialize our technology and product candidates may be impaired.
  • Our internal computer systems, or those of our CROs or other contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of our product development programs.
  • Our proprietary information, or that of our customers, suppliers and business partners, may be lost or we may suffer security breaches.
  • Our rights to develop and commercialize our technology, our current in-development products, and our other future product candidates are subject, in large part, to the terms and conditions of licenses granted to us by others, such as Cedars-Sinai Medical Center and Tracon Pharmaceuticals, Inc. If we fail to comply with our obligations in the agreements under which we in-license or acquire development or commercialization rights to products, technology, or data from third parties, we could lose such rights that are important to our business.
  • We may not be successful in obtaining necessary rights to any product candidates we may develop through acquisitions and in-licenses.
  • We may become involved in lawsuits to protect or enforce our owned or in-licensed patents or other intellectual property, which could be expensive, time-consuming, and unsuccessful.
  • Third parties may initiate legal proceedings alleging that we are infringing misappropriating, or otherwise violating their intellectual property rights, the outcome of which would be uncertain and could significantly harm our business.
  • We may be subject to claims by third parties asserting that we or our employees, consultants, and advisors have misappropriated their intellectual property or claiming ownership of what we regard as our own intellectual property.
  • Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our products.
  • Any trademarks we may obtain may be infringed or successfully challenged, resulting in harm to our business.
  • If we are unable to protect the confidentiality of our proprietary information, know-how, and trade secrets, the value of our current in-development products or other future product candidates could be adversely affected, and our business and competitive position would be harmed.
  • If we or our licensors do not obtain patent term extension and data exclusivity for any product candidates we or our licensors may develop, our business may be materially harmed.
  • Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment, and other requirements imposed by government patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.
  • We may not be able to protect our intellectual property rights throughout the world.
  • Risks Related to Healthcare Laws and Other Legal Compliance Matters
  • If we successfully commercialize our current in-development products or one of our future product candidates, failure to comply with our reporting and payment obligations under U.S. governmental pricing programs could have a material adverse effect on our business, financial condition, and results of operations.
  • Our current and future relationships with healthcare professionals, principal investigators, consultants, customers, and third-party payors in the United States and elsewhere may be subject, directly or indirectly, to applicable anti-kickback, fraud and abuse, false claims, physician payment transparency, health information privacy and security, and other healthcare laws and regulations, which could expose us to penalties.
  • Changes in healthcare policies, laws, and regulations may impact our ability to obtain approval for, or commercialize our current in-development products or our future product candidates, if approved.
  • We are subject to privacy and data security laws, rules, regulations, policies, industry standards, and contractual obligations, and our failure to comply with them could harm our business.
  • Any clinical trial programs we conduct or research collaborations we enter into in the European Economic Area may subject us to the General Data Protection Regulation.
  • Our product candidates may be subject to government price controls that may affect our revenue.
  • If we fail to comply with environmental, health, and safety laws and regulations, we could become subject to fines or penalties or incur costs that could harm our business.
  • We are subject to U.S. and certain foreign export and import controls, sanctions, embargoes, anti-corruption laws, and anti-money laundering laws and regulations. Compliance with these legal standards could impair our ability to compete in domestic and international markets. We can face criminal liability and other serious consequences for violations, which can harm our business.
  • We rely, and expect to continue to rely, on third parties to conduct, supervise, and monitor our preclinical studies and clinical trials. If those third parties do not perform satisfactorily, including failing to meet deadlines for the completion of such trials or failing to comply with regulatory requirements, we may be unable to obtain regulatory approval for our product candidates or any other product candidates that we may develop in the future.
  • We have entered into, and may in the future enter into, certain collaboration agreements and strategic alliances to maximize the potential of our product candidates, and we may not realize the anticipated benefits of such collaborations or alliances. We expect to continue to form collaborations in the future with respect to our product candidates, but may be unable to do so or to realize the potential benefits of such transactions, which may cause us to alter or delay our development and commercialization plans.
  • If we are not able to establish future collaborations on commercially reasonable terms, we may have to alter our development and commercialization plans for one or more of our other development programs.
  • Our current and any future collaborations are not a guarantee of success, and all collaborations are as risky, or riskier, than undertaking the activities ourselves.

Legal proceedings

From time to time, we may become involved in material legal proceedings or be subject to claims arising in the ordinary course of our business. Regardless of outcome, such proceedings or claims can have an adverse impact on us because of defense and settlement costs, diversion of resources, and other factors, and there can be no assurances that favorable outcomes will be obtained. We are not presently party to any legal proceedings material to our operations or of which any of our property is the subject, nor are we aware of any such proceedings that are contemplated by a government authority.

The opening of Item 3, Legal Proceedings.3

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
    SEC EDGAROther events
  17. 17
  18. 18
  19. 19
  20. 20
    SEC EDGAROther events
  21. 21
  22. 22
    SEC EDGAROther events
  23. 23
    SEC EDGAROther events
  24. 24
  25. 25
    SEC EDGAROther events
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31